No-Spa Forte (Drotaverine Hydrochloride)

No-Spa Forte is an antispasmodic that acts on smooth muscle of the gastrointestinal and genitourinary systems.

• Abdominal pain: reduces painful intestinal cramping by relaxing gut smooth muscle.
• Menstrual cramps: eases uterine muscle spasms, providing relief during dysmenorrhea.
• Biliary colic: relaxes biliary ducts to alleviate pain from gallstone‑induced spasms.
• Urinary tract spasm: diminishes bladder and ureteral muscle contractions that cause discomfort.
• Gastrointestinal smooth muscle spasm: improves motility‑related discomfort by decreasing tone in the GI tract.

• Drotaverine hydrochloride inhibits phosphodiesterase‑4, leading to increased intracellular cyclic AMP levels, which cause smooth‑muscle relaxation. It also blocks calcium channels, further reducing muscle contractility. The combined actions result in decreased spasm of gastrointestinal, biliary, urinary and uterine smooth muscle without significant anticholinergic effects.

Common Side Effects

• Nausea: mild stomach upset occurring in some patients.
• Dizziness: transient light‑headedness, especially after the first dose.
• Dry mouth: reduced salivation reported occasionally.
• Headache: mild to moderate headache may develop.
• Flushing: temporary warmth and redness of the skin.
• Hypotension: slight drop in blood pressure in susceptible individuals.

Serious or Rare Side Effects

• Allergic reactions: rash, itching or swelling that may indicate hypersensitivity.
• Severe skin eruption: rare cases of Stevens‑Johnson syndrome.
• Anaphylaxis: life‑threatening allergic response requiring immediate medical care.
• Cardiac arrhythmia: irregular heart rhythm reported in isolated cases.
• Severe hypotension: marked blood‑pressure fall leading to dizziness or fainting.
• Hepatic dysfunction: rare liver enzyme elevations.

Before initiating therapy, consider the following precautions:

• Renal or hepatic impairment: assess function and adjust use if necessary.
• Elderly patients: start with the lowest effective dose and monitor closely.
• Hypersensitivity: avoid if the patient has known allergy to drotaverine or similar compounds.
• Concomitant antihypertensives: monitor blood pressure for additive hypotensive effect.
• Use with other antispasmodics: avoid concurrent use to reduce risk of excessive muscle relaxation.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Drotaverine may interact with several drug classes.

Major Interactions (Avoid)

• Other antispasmodics (e.g., papaverine, hyoscine): risk of excessive smooth‑muscle relaxation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase drotaverine plasma levels.
• Antihypertensive agents: additive hypotensive effect.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs: possible enhancement of antispasmodic effect.
• Diuretics: monitor electrolytes and blood pressure.
• Beta‑blockers: watch for amplified cardiovascular effects.